GluA1

GluA1
Name	GluA1
Uniprot	P42262
Organism	Human
Length	811 aa (isoforms vary)

GluA1 GluA1 is an ionotropic glutamate receptor subunit predominantly expressed in the vertebrate central nervous system and encoded by the human GRIA1 gene. It assembles into AMPA-type receptor complexes that mediate fast excitatory neurotransmission and contribute to synaptic plasticity implicated in learning and memory. Research on GluA1 intersects with studies of Hippocampus, Prefrontal cortex, Synaptic plasticity, Long-term potentiation, and disorders such as Schizophrenia and Alzheimer's disease.

Introduction

GluA1 is one of four canonical AMPA receptor subunits described during investigations by groups working in laboratories associated with Cold Spring Harbor Laboratory, Max Planck Society, and Scripps Research. Early molecular cloning efforts linked GluA1 to findings from teams at University of Oxford, Massachusetts Institute of Technology, and Columbia University. Functional characterization employed preparations from model organisms including Mus musculus, Rattus norvegicus, and Danio rerio to map roles in synaptic transmission examined alongside protocols used in Patch clamp recordings, Electrophysiology, and Behavioral neuroscience.

Structure and isoforms

The GluA1 protein adopts the conserved architecture of the ionotropic glutamate receptor family described in structural studies from groups at European Molecular Biology Laboratory, Stanford University, and Max Planck Institute for Biophysical Chemistry. Cryo-electron microscopy and X-ray crystallography defined domains analogous to structures reported by teams at Yale University and University of California, San Francisco: an extracellular amino-terminal domain, ligand-binding domain, transmembrane domain forming the ion channel pore, and a cytoplasmic carboxyl-terminal domain. Alternative splicing and post-transcriptional editing generate isoforms comparable to splice variants characterized in publications from Harvard University and Johns Hopkins University, affecting trafficking motifs and phosphorylation sites recognized by kinases studied at National Institutes of Health.

Gene and expression

The GRIA1 gene locus was mapped in genetic screens and genomic projects such as initiatives from Human Genome Project consortia, with annotation contributions from groups at Wellcome Trust Sanger Institute and European Bioinformatics Institute. Expression profiling using methods developed at Broad Institute and Cold Spring Harbor Laboratory shows high GRIA1 transcript abundance in regions including the Hippocampus, Cerebral cortex, and Amygdala, with developmental regulation traced in studies from University College London and Stanford University Medical Center. Regulatory sequences and promoter elements were analyzed in comparative genomics work alongside datasets from ENCODE and GTEx.

Function and synaptic role

GluA1-containing receptors mediate rapid excitatory postsynaptic currents studied in paradigms developed at University of Cambridge and University of California, Berkeley. Their role in activity-dependent insertion during paradigms of Long-term potentiation and Long-term depression has been demonstrated in experiments influenced by approaches from Cold Spring Harbor Laboratory and Salk Institute for Biological Studies. Behavioral consequences of GluA1 manipulation have been assessed in learning paradigms such as those used at Princeton University and University of Edinburgh, linking receptor dynamics to models of Working memory and Spatial navigation.

Regulation and trafficking

Trafficking of GluA1-containing AMPA receptors involves phosphorylation by kinases like Protein kinase A, Calcium/calmodulin-dependent protein kinase II, and ubiquitination pathways studied at Max Planck Institute of Neurobiology. Interactions with scaffold proteins and trafficking adaptors, characterized in work from Massachusetts General Hospital and Karolinska Institute, include binding partners that influence synaptic incorporation during plasticity protocols common to laboratories at New York University and University of California, San Diego. Endocytic routes and recycling pathways for GluA1 rely on machinery described in research from Harvard Medical School and University of Michigan.

Clinical relevance and associated disorders

Alterations in GRIA1 expression or GluA1 function have been implicated in neuropsychiatric and neurodegenerative conditions investigated by consortia including Psychiatric Genomics Consortium and clinical centers such as Mayo Clinic and Mount Sinai Health System. Associations link GluA1 dysfunction with phenotypes in Schizophrenia, cognitive decline in Alzheimer's disease, seizure susceptibility observed in studies at Cleveland Clinic, and synaptopathies relevant to Autism spectrum disorder cohorts analyzed at University of California, Los Angeles. Therapeutic strategies targeting AMPA receptors have been pursued by biotechnology companies and academic spinouts from Biogen and Roche alongside clinical trial networks coordinated by National Institutes of Health.

Research tools and experimental findings

Tools for studying GluA1 include genetic models such as knockout and knock-in mice generated at facilities like Jackson Laboratory and transgenic lines developed at European Mouse Mutant Archive. Antibodies, ligands, and small molecules characterized in studies from Pfizer and academic chemistry groups have been used in assays established at Cold Spring Harbor Laboratory and Scripps Research Institute. Key experimental findings were reported in journals associated with editorial offices at Nature Publishing Group, Cell Press, and Proceedings of the National Academy of Sciences and leveraged methods like Optogenetics, In vivo imaging, and high-resolution electrophysiology pioneered at institutions including MIT and University of California, San Francisco.

Category:Proteins